Identification of novel non-toxic and anti-angiogenic α-fluorinated chalcones as potent colchicine binding site inhibitors

α-Trifluoromethyl Chalcones as Potent Anticancer Agents for Androgen Receptor-Independent Prostate Cancer

(2021) Yohei Saito et al.   MOLECULES

Discovery of novel tubulin/HDAC dual-targeting inhibitors with strong antitumor and antiangiogenic potency

(2021) Yingge Wang et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Integration of oncology and palliative care: a Lancet Oncology Commission

(2018) Stein Kaasa et al.   LANCET ONCOLOGY

Synthesis, Evaluation, and Mechanism Study of Novel Indole-Chalcone Derivatives Exerting Effective Antitumor Activity Through Microtubule Destabilization in Vitro and in Vivo

(2016) Jun Yan et al.   JOURNAL OF MEDICINAL CHEMISTRY

De novo design of VEGFR-2 tyrosine kinase inhibitors based on a linked-fragment approach

(2016) Yi-zhou Liu et al.   JOURNAL OF MOLECULAR MODELING

Antivascular and antitumor properties of the tubulin-binding chalcone TUB091

(2016) María-Dolores Canela et al.   Oncotarget

Combretastatin A-4 efficiently inhibits angiogenesis and induces neuronal apoptosis in zebrafish

(2016) Yun-Wei Shi et al.   Scientific Reports

Tubulin Colchicine Binding Site Inhibitors as Vascular Disrupting Agents in Clinical Developments

(2015) Ya-Ting Ji et al.   CURRENT MEDICINAL CHEMISTRY

Recent advances in vascular disrupting agents in cancer therapy

(2014) Elena Porcù et al.   Future Medicinal Chemistry

Targeting caspases in cancer therapeutics

(2013) Patrick Hensley et al.   BIOLOGICAL CHEMISTRY

Phase II trial of combretastatin A4 phosphate, carboplatin, and paclitaxel in patients with platinum-resistant ovarian cancer

(2011) M. Zweifel et al.   ANNALS OF ONCOLOGY

Combretastatin-like chalcones as inhibitors of microtubule polymerization. Part 1: Synthesis and biological evaluation of antivascular activity

(2009) Sylvie Ducki et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Antivascular Actions of Microtubule-Binding Drugs

(2009) E. L. Schwartz   CLINICAL CANCER RESEARCH